Dr. Jastreboff is an Obesity Medicine physician-scientist, board certified in adult Endocrinology and Metabolism, Pediatric Endocrinology, and Obesity Medicine. She is nationally and internationally recognized in the Obesity Medicine field for developing Clinical Practice Guidelines (2016) for The Comprehensive Care of Patients with Obesity (AACE/ACE), serving on the Board of Directors for the American Board of Obesity Medicine (ABOM), educating the next generation of Obesity Medicine physicians by teaching annually at Harvard Blackburn Treating Obesity course and the Columbia/Cornell Obesity course, and conducting cutting-edge clinical translational obesity research. Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications. Recently, Dr. Jastreboff served as the lead author on the SURMOUNT-1 trial investigating novel GIP/GLP-1 receptor agonist, tirzepatide, for the treatment of obesity (Jastreboff, et al., NEJM, 2022).

Clinically, Dr. Jastreboff specializes in sophisticated use of anti-obesity medication combinations to help patients reach their weight and health goals. She mainly sees patients for obesity treatment and weight management and additionally cares for patients with prediabetes and diabetes.

Dr. Jastreboff is board certified in Internal Medicine, Pediatrics, Endocrinology and Metabolism, Pediatric Endocrinology, and Obesity Medicine.

She completed her PhD at Yale University's Investigative Medicine Program focused on clinical translational investigation with a dissertation entitled “Neural Response to Food Cues and Stress in Individuals with Obesity".

Dr. Jastreboff's research is supported by NIH/NIDDK (R01s) and industry funded global, multi-center clinical trials.